Search
Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase
go.drugbank.com/drugs/DB18681ExperimentalAutologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy.
Sulfaisodimidine
go.drugbank.com/drugs/DB13283ExperimentalSulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been
Amilomotide
go.drugbank.com/drugs/DB05150InvestigationalCAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease.
XL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).
Ibuzatrelvir
go.drugbank.com/drugs/DB19451InvestigationalAre at Risk for Severe Disease). … Ibuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but
GlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Alfaxalone
go.drugbank.com/drugs/DB11371ExperimentalVet approvedAlfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic.
Lomerizine
go.drugbank.com/drugs/DB14065ExperimentalLomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective central nervous system (CNS) effects. … [A245383] This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an
AVR-RD-01
go.drugbank.com/drugs/DB17651InvestigationalAVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. … It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence.